| 2015年
12月31日 | 2016年
12月31日 | 2017年
12月31日 | 2018年
12月31日 | 2019年
12月31日 | 2020年
12月31日 | 2021年
12月31日 | 2022年
12月31日 | 2023年
12月31日 |
|---|
| Revenue | 97 | 254 | 435 | 627 | 846 | 1,022 | 908 | 1,352 | 1,964 |
|---|
| Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization | - | - | - | - | - | - | - | 1,035 | - |
|---|
| Cost of revenue | - | - | - | - | - | - | - | 1,035 | 1,503 |
|---|
| Selling, General and Administrative Expense | 75 | 161 | 206 | 235 | 257 | 223 | 219 | 269 | 358 |
|---|
| Depreciation and amortization expenses | 7 | 17 | 32 | 45 | 61 | 61 | 60 | 67 | 123 |
|---|
| Loss on disposal of non-strategic assets | - | - | - | - | 10 | -1 | - | - | -8 |
|---|
| Goodwill impairment | - | 161 | - | - | 200 | 215 | - | - | - |
|---|
| Right-of-use assets impairment | - | - | - | - | - | - | - | - | 24 |
|---|
| Change in fair value of contingent consideration | - | -2 | 0 | -4 | -4 | 4 | 13 | -24 | 18 |
|---|
| Total operating expenses | - | - | - | - | - | - | - | 1,348 | 2,035 |
|---|
| Operating income (loss) | -43 | -237 | -73 | -47 | -307 | -271 | -42 | 4 | -71 |
|---|
| Interest income | - | - | 2 | 3 | 4 | 3 | 0 | 1 | 5 |
|---|
| Interest expense | - | - | 4 | 5 | 15 | 28 | 25 | 16 | 54 |
|---|
| Impairment of equity method investments | - | - | - | - | - | 47 | - | - | - |
|---|
| Gain from equity method investees | -28 | -1 | -2 | -5 | -9 | 10 | 13 | 5 | 1 |
|---|
| Gain from equity method investees | -28 | -1 | -2 | -5 | -9 | 10 | 13 | 5 | 1 |
|---|
| Gain on transfer of membership | - | - | - | - | - | - | 46 | - | - |
|---|
| Gain on transfer of membership | - | - | - | - | - | - | 46 | - | - |
|---|
| Gain (Loss) on Extinguishment of Debt | - | - | - | - | - | -5 | - | -10 | -21 |
|---|
| Gain (Loss) On Repayment Of Debt | - | - | - | - | - | - | -21 | -10 | - |
|---|
| Change in tax receivables agreement liability | - | - | - | - | - | - | - | 46 | 62 |
|---|
| Change in tax receivables agreement liability | - | - | - | - | - | - | - | 46 | 62 |
|---|
| Other income (expense), net | - | - | - | - | - | - | - | 0 | -1 |
|---|
| Other income (expense), net | - | - | - | - | - | - | - | 0 | -1 |
|---|
| Loss before income taxes | 343 | -238 | -76 | -54 | -327 | -338 | -30 | -62 | -202 |
|---|
| Loss before income taxes | 343 | -238 | -76 | -54 | -327 | -338 | -30 | -62 | -202 |
|---|
| Income Tax Expense (Benefit) | 24 | -11 | -7 | 0 | -22 | -4 | 0 | -43 | -89 |
|---|
| Income Tax Expense (Benefit) | 24 | -11 | -7 | 0 | -22 | -4 | 0 | -43 | -89 |
|---|
| Loss from continuing operations | - | - | - | - | - | - | - | -19 | -113 |
|---|
| Loss from continuing operations | - | - | - | - | - | - | - | -19 | -113 |
|---|
| Loss from discontinued operations, net of tax | - | - | - | - | - | - | - | -0 | - |
|---|
| Loss from discontinued operations, net of tax | - | - | - | - | - | - | - | -0 | - |
|---|
| Loss before preferred dividends and accretion of Series A Preferred Stock | 332 | -160 | -61 | -53 | -302 | -334 | -38 | -19 | -113 |
|---|
| Net (loss) attributable to common shareholders of Evolent Health, Inc. - Basic | 330 | -160 | -61 | - | - | - | -38 | -19 | -142 |
|---|
| Dividends and accretion of Series A Preferred Stock | - | - | - | - | - | - | - | - | 29 |
|---|
| Net (loss) attributable to common shareholders of Evolent Health, Inc., Inc. - Diluted | 320 | -160 | -61 | - | - | - | -38 | -19 | -142 |
|---|
| Net (loss) attributable to common shareholders of Evolent Health, Inc. - Basic | 330 | -160 | -61 | - | - | - | -38 | -19 | -142 |
|---|
| Continuing operations, basic (in dollars per share) | - | - | - | - | - | - | -0.35 | -0.2 | -1.28 |
|---|
| Continuing operations, diluted (in dollars per share) | - | - | - | - | - | - | -0.35 | -0.2 | -1.28 |
|---|
| Discontinued operations basic (in dollars per share) | - | - | - | - | - | - | -0.09 | - | - |
|---|
| Discontinued operations diluted (in dollars per share) | - | - | - | - | - | - | -0.09 | - | - |
|---|
| Basic loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share) | 13.14 | -3.55 | -0.94 | - | - | - | -0.44 | -0.2 | -1.28 |
|---|
| Diluted loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share) | 6.93 | -3.55 | -0.94 | - | - | - | -0.44 | -0.2 | -1.28 |
|---|
| Net (loss) attributable to common shareholders of Evolent Health, Inc., Inc. - Diluted | 320 | -160 | -61 | - | - | - | -38 | -19 | -142 |
|---|
| Continuing operations, basic (in dollars per share) | - | - | - | - | - | - | -0.35 | -0.2 | -1.28 |
|---|
| Continuing operations, diluted (in dollars per share) | - | - | - | - | - | - | -0.35 | -0.2 | -1.28 |
|---|
| Discontinued operations basic (in dollars per share) | - | - | - | - | - | - | -0.09 | - | - |
|---|
| Discontinued operations diluted (in dollars per share) | - | - | - | - | - | - | -0.09 | - | - |
|---|
| Basic loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share) | 13.14 | -3.55 | -0.94 | - | - | - | -0.44 | -0.2 | -1.28 |
|---|
| Diluted loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share) | 6.93 | -3.55 | -0.94 | - | - | - | -0.44 | -0.2 | -1.28 |
|---|
| Net Income (Loss) | 332 | -160 | -61 | -53 | -302 | -334 | -38 | -19 | -113 |
|---|
| Net Income (Loss) Available to Common Stockholders, Basic | 330 | -160 | -61 | - | - | - | -38 | -19 | -142 |
|---|
| Foreign currency translation adjustment | - | - | - | - | - | - | - | -1 | -0 |
|---|
| Total comprehensive loss attributable to common shareholders of Evolent Health, Inc. | - | - | - | -53 | -302 | -334 | -38 | -20 | -142 |
|---|
| Net Income (Loss) | 332 | -160 | -61 | -53 | -302 | -334 | -38 | -19 | -113 |
|---|
| Net Income (Loss) Available to Common Stockholders, Basic | 330 | -160 | -61 | - | - | - | -38 | -19 | -142 |
|---|
| Foreign currency translation adjustment | - | - | - | - | - | - | - | -1 | -0 |
|---|
| Total comprehensive loss attributable to common shareholders of Evolent Health, Inc. | - | - | - | -53 | -302 | -334 | -38 | -20 | -142 |
|---|